Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_assertion description "[In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non-small cell lung cancer (NSCLC) harboring ROS1 fusions; however, cancers eventually develop crizotinib resistance due to acquired mutations such as G2032R in ROS1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_assertion evidence source_evidence_literature NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_assertion SIO_000772 25351743 NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_assertion wasDerivedFrom befree-2016 NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_assertion wasGeneratedBy ECO_0000203 NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.
- befree-2016 importedOn "2016-02-19" NP1233257.RALgs1iF147gTJCvyk2aB5-wRBFuAUkwVe7y1NcJGG3Pc130_provenance.